A prospective study of cortical scarring in acute febrile pyelonephritis in adults: clinical and bacteriological characteristics.
Previous reports have demonstrated lesions on computerized axial tomography (CT), and nuclear scintigraphy (DMSA) in acute pyelonephritis (PN). We undertook a prospective study of all patients presenting to our hospital with PN over 40 months. Patients who fulfilled diagnostic criteria, were treated with intravenous antibiotics. Excluding two who were pregnant, all patients had imaging by intravenous urography (IVU), CT and DMSA during their admission. Urine samples were collected prior to treatment. Patients without IVU evidence of cortical scarring but with parenchymal defects on CT and/or DMSA underwent a repeat DMSA three or more months after the acute episode. Of the 164 patients, 142 were female. E. coli was found in 116 patients. Forty-six patients had an abnormality on IVU. Of the 106 patients without IVU evidence of cortical scarring, 59 had a defect on CT and/or DMSA. Late DMSA scans in 35 of these 59 patients showed a persistent abnormality in 77%. E. coli characteristics such as P-fimbriae and Type 1 fimbriae were not predictive of acute imaging abnormalities. Inhibition of E. coli growth by the addition of EDTA was highly predictive of acute CT and DMSA abnormalities with a sensitivity of 83.3% and a specificity of 82.8%. Acute pyelonephritis is often associated with acute CT and/or DMSA abnormalities which may evolve into renal cortical scars. Acute scan abnormalities can be predicted by the presence of E. coli which were susceptible to EDTA in culture. Late scarring could not be predicted by clinical features, response to treatment or antibiotic used.
Fraser
I R
IR
Department of Nephrology, Royal Melbourne Hospital, Melbourne, Australia.
Birch
D
D
Fairley
K F
KF
John
S
S
Lichtenstein
M
M
Tress
B
B
Kincaid-Smith
P S
PS
D000208:Acute Disease; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001706:Biopsy; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D007672:Kidney Cortex / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011704:Pyelonephritis / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology*; D016869:Ureaplasma Infections / Q000188:drug therapy / Q000473:pathology; D016990:Ureaplasma urealyticum / Q000302:isolation & purification
D000900:Anti-Bacterial Agents